Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483681 | 0.80 | ALOX5AP (0.40) | MAPTSMN1; SMN2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL13089333 | 0.73 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL2819722 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL2821304 | 0.72 | CYP1A2 (0.36) | CYP1A2 | |
| Bromide SCHEMBL668001 | 0.72 | — | — | |
| SCHEMBL31241182 | 0.71 | MAPT (0.61) | MAPTSMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL28581728 | 0.71 | MAPT (0.61) | MAPTSMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL4264723 | 0.69 | ALOX5AP (0.39) | — | |
| SCHEMBL668390 | 0.69 | ACHE (0.36) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27419619 | 0.68 | CYP1A2 (0.51) | MAPTCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922320-B1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-27 | — | — | EP | claimed |
| US-8557819-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-10-15 | — | — | US | disclosed |
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2012-02-23 | — | — | US | disclosed |
| EP-1922320-B1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | TPMT, DHFR, S1PR5 | MAPT 2187/4885SMN1; SMN2 1907/4885MEN1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.